AZ, IMS To Build Disparate Data Sets Into Broader Outcomes Consensus
Individual deals with payers or information providers won’t provide pharma with the breadth of outcomes data they need to secure reimbursement for their drugs. A far broader stakeholder consensus is required.
You may also be interested in...
COPD stalwarts Symbicort and Seretide never have been compared head-to-head in the clinic but Swedish researchers now have analyzed the pair’s respective association with pneumonia, using Sweden’s modern infrastructure and national databases. The review concluded that the AstraZeneca compound soundly beats GlaxoSmithKline’s, based on real-world evidence.
A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data.
A wave of research-based collaborations between pharmaceutical companies and payors is enabling a new level of credibility, trust, and joint efforts to enhance patient care.